Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ancestry and pharmacogenetics of antileukemic drug toxicity.

Blood - 15 May 2007

Kishi Shinji, Cheng Cheng, French Deborah, Pei Deqing, Das Soma, Cook Edwin H, Hijiya Nobuko, Rizzari Carmelo, Rosner Gary L, Frudakis Tony, Pui Ching-Hon, Evans William E, Relling Mary V

Abstract excerpt

Treatment-related toxicity in acute lymphoblastic leukemia (ALL) can not only be life threatening but may also affect relapse risk. In 240 patients, we determined whether toxicities were related to 16 polymorphisms in genes linked to the pharmacodynamics of ALL chemotherapy, adjusting for age, ra...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug-Related Side Effects and Adverse Reactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Methotrexate

Share to Models, Biological

Share to Pharmacogenetics

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to Racial Groups

Share to Remission Induction

Source

Open in PubMed Open full text

Identifiers

PMID: 17264302
DOI: 10.1182/blood-2006-10-054528
PMCID: PMC1885506

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17264302-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ancestry and pharmacogenetics of antileukemic drug toxicity.PMID 17264302Read ↗

Pharmacogenetic considerations for acute lymphoblastic leukemia therapies.Semantic proximity Read ↗

Association of genetic polymorphisms with hepatotoxicity in patients with childhood acute lymphoblastic leukemia or lymphoma.Semantic proximity Read ↗

Polygenic Pharmacogenomic Markers as Predictors of Toxicity Phenotypes in the Treatment of Acute Lymphoblastic Leukemia: A Single-Center Study.Semantic proximity Read ↗

The Promise of Pharmacogenomics in Reducing Toxicity during Acute Lymphoblastic Leukemia Maintenance TreatmentSemantic proximity Read ↗

Chemotherapy-related hyperbilirubinemia in pediatric acute lymphoblastic leukemia: a genome-wide association study from the AIEOP-BFM ALL Study GroupSemantic proximity Read ↗

Gene polymorphisms in the folate metabolism and their association with MTX-related adverse events in the treatment of ALL.Semantic proximity Read ↗

Pharmacoepigenetics in childhood acute lymphoblastic leukemia: involvement of miRNA polymorphisms in hepatotoxicity.Semantic proximity Read ↗

Involvement of C677T MTHFR variant but not A1298C in methotrexate-induced toxicity in acute lymphoblastic leukemia.Semantic proximity Read ↗

Implementation of Pharmacogenetics to Individualize Treatment Regimens for Children with Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Methylene tetrahydrofolate reductase gene polymorphism in Egyptian children with acute lymphoblastic leukemia.Semantic proximity Read ↗

Pharmacogenetics of induction therapy-related toxicities in childhood acute lymphoblastic leukemia patients treated with UKALL 2003 protocol.Semantic proximity Read ↗

Pharmacogenetics of outcome in children with acute lymphoblastic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.